Indivior announced that the Food and Drug Administration (FDA) has approved Perseris, a once-monthly subcutaneous (SC) risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults.

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month. Data showed clinically relevant levels of risperidone were achieved after the first injection without a loading dose or any supplemental oral risperidone doses. 

Perseris was evaluated in a Phase 3, randomized, double-blind, placebo-controlled, 8-week study in adult patients experiencing acute exacerbations of schizophrenia (N=354). Its efficacy was demonstrated by an improvement in the Positive and Negative Syndrome Scale (PANSS) total score at day 57 (primary endpoint). Also, treatment with Perseris showed a statistically significant improvement in Clinical Global Impression Severity of Illness (CGI-S) at day 57. 


Continue Reading

Related Articles

The systemic safety profile of Perseris was consistent with the established safety of oral risperidone, according to data from 814 adults with schizophrenia who received ≥1 dose during the trials. Weight gain, sedation, somnolence, and musculoskeletal pain were the most common systemic adverse effects reported; injection site reactions such as pain and reddening of the skin were also commonly reported. Perseris carries a Boxed Warning indicating an increased risk of mortality in elderly patients with dementia-related psychosis; it is not approved for use in these patients. 

Perseris is available in strengths of 90mg and 120mg and is supplied in single-dose kits containing the risperidone powder, delivery system, and safety needle.

For more information call (877) 782-6966 or visit Indivior.com.

This article originally appeared on MPR